Inactivation of the p53 tumor suppressor gene is a commonevent in the development of colon cancer. We usedata collected as part of a multicenter case-control study of colon cancer to evaluate associations between p53 mutations and diet and lifestyle factors. p53 mutational status was determined for 1458 incident cases of colon cancer using single-strand conformational polymorphism/sequencing of exons 5–8. We determined associations among those with and without mutations compared with population-based controls (N = 2410) and to cases with p53 mutations compared with cases without p53 mutations. Associations also were examined by location and function of specific types of p53 mutations. p53 mutations were identified in tumors in 47.1% of cases; 81.9% of people with mutations had a missense mutation. Cases with a p53 mutation were more likely to consume a Western-style diet, compared with controls [odds ratio (OR), 2.03; 95% confidence interval (CI), 1.53–2.69], than were cases who were p53 wild type (Wt), compared with controls (OR, 1.57;95% CI, 1.20–2.06). Specific components of the Western-style diet, including diets with a high glycemic load (mutation versus control: OR, 1.48; 95% CI, 1.11–1.98 and Wt versus control: OR, 0.98; 95% CI, 0.75–1.28) and diets high in red meat, fast food, and trans-fatty acid (mutation versus control: OR, 1.92; 95% CI, 1.47–2.50 and Wt versus control: OR, 1.39; 95% CI, 1.08–1.80) appeared to be most strongly associated with p53 mutations. Diets with a high glycemic load (relative to lowest intake) were significantly associated with missense mutations (OR, 1.69; 95% CI, 1.23–2.33 comparing p53+ to controls and OR, 1.72; 95% CI, 1.19–2.50 comparing cases p53+ to cases p53 Wt), as were diets high in red meat, fast food, and trans-fatty acids (OR, 1.92; 95% CI, 1.14–2.56 comparing p53+ to controls and OR, 1.40; 95% CI, 1.00–1.98 comparing cases p53+ to cases p53 Wt). Physical inactivity, large body mass index, cigarette smoking, using aspirin/nonsteroidal anti-inflammatory drugs, and other dietary factors appeared to be comparably associated with colon cancer in those with and without p53 mutations. These data suggest that components of a Western-style diet such as high consumption of red meat and foods that increase glycemic load are associated with a p53 disease pathway.

The p53 tumor suppressor gene is involved in numerous cellular processes, including induction of apoptosis and cell cycle arrest (1, 2). Given the high prevalence of genetic alterations in the p53 gene found in tumors, p53 is thought to play a role in the carcinogenic process of many forms of cancer. The reported frequency of alterations in the p53 gene in colon tumors varies, with early reports suggesting that 75% of colon cancers had an alteration, although more recent estimates suggest that 40–50% of colon tumors have alterations (3, 4, 5). Most mutations in colon tumors have been reported as missense mutations, and studies that have examined the entire gene report that 87% of p53 mutations in colon tumors occur in exons 5–8, the recognized regions that contain hot spots for p53 mutations in human neoplasia (6). Over half of the mutations in colon tumors have been reported as occurring in one of three codons: 175, 248, and 273, and most are G:C to A:T transitions (5, 6).

The diet, lifestyle, environmental, or genetic factors that are associated with p53 mutations in colon tumors are unknown; however, there is precedence for environmental factors affecting the type and/or location of p53 mutations in other tumors. Hepatomas associated with aflatoxin B1 and hepatitis B commonly show a mutation in codon 249 (6). Lung and esophageal cancer, diseases associated with tobacco usage, show frequent G:C to T:A transversions (6). Dietary components have been associated with specific Ki-ras mutations in colon tumors (7). Given the important role of diet and lifestyle factors to the etiology of colon cancer overall, it is a reasonable hypothesis that they are associated with p53 mutations and possibly with the location and type of mutation (8). In this study, we use data collected as part of a multicenter case-control study to evaluate how diet and other lifestyle factors relate to p53 mutations in colon tumors.

Study participants were African American, white, or Hispanic and were from either the KPMCP3 of northern California, an eight county area in Utah (Davis, Salt Lake, Utah, Weber, Wasatch, Tooele, Morgan, and Summit counties), or the Twin Cities metropolitan area in Minnesota (9). Eligibility criteria for cases included diagnosis with first-primary incident colon cancer (International Classification of Diseases for Oncology 2nd edition codes, 18.0 and 18.2–18.9) between October 1, 1991, and September 30, 1994, between 30 and 79 years of age at time of diagnosis, and mentally competent to complete the interview. Cases with adenocarcinoma or carcinoma of the rectosigmoid junction or rectum (defined as the first 15 cm from the anal opening), with known familial adenomatous polyposis, ulcerative colitis, or Crohn’s disease were not eligible. Of all cases identified, 75.6% of those we were able to contact participated in the study, and 96% of cases identified were contacted.

Controls, in addition to the eligibility criteria for cases, could never have had a previous colorectal cancer. Controls were selected from eligibility lists from the KPMCP and driver’s license lists in Minnesota, and from driver’s license lists, random-digit-dialing, or Health Care Finance Administration lists for Utah. These methods have been described in detail (9, 10). Of all controls selected, 63.7% participated; the contact rate at KPMCP was 97%, in Utah it was 94%, and in Minnesota it was 72%.

Data Collection.

Trained and certified interviewers collected diet and lifestyle data (11). The referent period for the study was the calendar year ∼2 years before date of diagnosis (cases) or selection (controls). Respondents were asked to recall information on demographic factors: physical activity (12); body size, including usual adult height and weight 2 and 5 years before diagnosis; use of aspirin and/or NSAIDs; cigarette-smoking history; medical and reproductive history, including use of hormone replacement therapy; and diet.

Dietary intake data were ascertained using an adaptation of the validated Coronary Artery Risk Development in Young Adults diet history questionnaire (13, 14). Participants were asked to determine which foods were eaten (using brand names of food items such as fast foods, cookies, crackers, and cereals, when possible), the frequency with which foods were eaten, and the type of fat used in preparation of foods. Three-dimensional food models were used to help participants estimate their usual serving size. Cue cards were used to provide a consistent prompt to help identify foods within broad categories. For categories in which many types of food might have been eaten (such as breakfast cereal), participants were asked to report the three most commonly eaten items. Detailed information was also obtained on foods eaten as additions to other foods (such as sugar added to cereal); standard amounts of additions were assigned per unit of the food item they accompanied. Nutrients were calculated using the Minnesota Nutrition Coordinating Center’s nutrient database, version 19; version 30 of the Minnesota Nutrition Coordinating Center’s database was used to obtain data on trans-fatty acids. Foods were grouped into categories of red meat, processed meats (including hot dogs, luncheon meat, and sausage), eggs, low-fat dairy products (including milk, yogurt, and cheese), fruit (including fresh, frozen, and canned fruits), vegetables, cruciferous vegetables, whole grains, and refined grains. The number of standard servings consumed from a food group was totaled for each individual. A dietary glycemic index was created so that dietary carbohydrates could be weighed by their metabolic effect (15).

Tissue Ascertainment and DNA Extraction.

Study respondents signed informed consent forms to have medical records, including tissue blocks, released. Detailed methods for obtaining tumor tissue have been discussed previously (16). Of the 2477 people for whom blocks were requested, DNA was extracted from 85.5%. Colon cancer tissue was microdissected, and DNA was extracted from formalin-fixed, paraffin-embedded tissue blocks as described previously (16). Briefly, after preparation of H&E and aniline blue slides, the study pathologist (W. S.) reviewed the slides and selected material. Material was scraped into a 1.5-ml microfuge tube, combined with digestion buffer, and incubated overnight at 55°C. Samples were then heated to 94°C for 10 min to inactivate the proteinase K. Although DNA was available from more women than men, there were no detected differences among those with and without tumor DNA by age at diagnosis, tumor site, or interview status. Likewise, we detected no statistically significant differences in diet, BMI, physical activity, cigarette smoking status, or NSAID use for those with and without tumor DNA.

p53 Analysis.

The exons and intron/exon boundaries of exons 5–8 of p53 were PCR amplified with the following primers (two sets of primers, a 5′ and 3′ set, were used to amplify the relatively large exon 5; “F” is the forward primer, “R” the reverse): 5-5′F:ttatctgttcacttgtgccc and 5-5′R:tcatgtgctgtgactgcttg; 5-3′F:ttccacacccccgcccggca and 5-3′R:accctgggcaaccagccctg; 6F:acgacagggctggttgccca and 6R:ctcccagagaccccagttgc; 7F:ggcctcatcttgggcctgtg and 7R:cagtgtgcagggtggcaagt; and 8F:gtttctgcctcttgcttctctttt and 8R:tctcctccaccgcttcttgt. Primers were dye labeled and a SSCP analysis of the respective PCR products was performed by electrophoresis in a nondenaturing gel and evaluation on an ABI 373 machine (17). Tumor samples corresponding to any abnormally migrating SSCP bands were reamplified with the respective primers tailed with UP and RP (and without dye labeling) for sequencing. PCR products were sequenced using prism Big Dye terminators and cycle sequencing with Taq FS DNA polymerase. DNA sequence was collected and analyzed on an ABI prism 377-automated DNA sequencer. All alterations were verified by sequencing in both directions.

SSCP was also performed on the respective blood germ-line DNA sample of any tumor with a non-hot spot missense mutation, insertion or deletion mutations that consisted of multiples of 3 bases, and splice site mutations. For hot spot mutations in which the same mutation was found in ≥10 tumors, SSCP was performed on a random sample of 10 of the respective normal samples. If abnormally migrating SSCP bands were seen in any germ-line DNA sample, then these samples were also sequenced to determine whether the germ-line DNA harbored the same genetic alteration as the respective tumor. Sequencing also was performed on the corresponding germ-line DNA for any tumor in which multiple genetic alterations within a particular exon were identified by the initial sequencing. Any samples with a germ-line mutation were excluded as a tumor mutation.

Statistical Methods.

Assessment of associations between diet and lifestyle factors and p53 mutations in tumors were determined using multiple logistic regression models. Data were evaluated comparing those with p53 mutations to those without p53 mutations, as well as those with and without p53 mutations in tumors to population-based controls. The case-control comparison was conducted to estimate the relative risk of developing disease with specific genetic mutations. The “case-case” comparison was conducted to evaluate etiological heterogeneity of the risk factors under study.

In addition to evaluating any mutation, we evaluated the most common types of mutations, such as those occurring at CpG dinucleotides. We evaluated missense, transition, and transversion mutations as well as frameshift, in-frame insertions and deletions, stop codon, and splice site. The hot spots of Arg273 and Arg248 were evaluated separately because these were the most common hot spot mutations observed. We assessed functional impact of mutations by looking at contact mutations that inactivate p53 by elimination of critical DNA contacts (Arg273, Arg248, Arg280, and Cys277) and structural mutations and noncontact missense mutations that appear to destabilize the structure of the core domain and location of mutation, including those located on the β sandwich, the L2 and L3 loops, and the LSH, including the helix (H2) portion of the protein (6, 17, 18). Specific types of mutations were assessed because other studies have shown specific mutations to have etiologic associations (6, 7, 8) and because missense mutations most closely correlate with IHC overexpression that has been done in other studies of associations (19).

Dietary data were analyzed for major dietary patterns found in the data set, as well as for major dietary components of those patterns (20). Dietary patterns were developed using factor analysis as described elsewhere using the SAS principal components program (20). After a varimax rotation, factor scores were saved for each individual. Two dietary patterns emerged that appeared to be important in this population. The food pattern arbitrarily labeled as “Western Diet” loaded heavily (factors with loadings of >0.30) on processed meats, red meat, fast-food meat, eggs, butter (men only), margarine, potatoes, high-fat dairy foods (men only), legumes, refined grains, added sugar (men only), sugar drinks (men only), and sugar desserts. The second dietary pattern, “Prudent Diet,” loaded heavily on all types of fruits and vegetables, whole grains, fish, and poultry. Physical activity was assessed using an indicator of long-term vigorous physical activity (21). We also assessed the BMI of weight (kg)/height (m)2, the use of aspirin and/or NSAIDs on a regular basis (defined as at least three times/week for 1 month), and the usual number of cigarettes smoked per day. Data were categorized into groups based on distribution in the control population.

We detected p53 mutations in tumors from 47.1% of the cases (Table 1); 48.4% of men and 45.4% of women had a tumor with a p53 mutation. Among those 65 years of age and older, 46% had a p53 mutation, whereas 48.5% of those younger than 65 years had a p53 mutation. The majority of p53 mutations were transitions (77%) rather than transversions (17.1%). Of specific types of mutations, 81.9% were missense, 9.5% were frameshift, 9.8% were stop codon, 2.9% were in-frame insertions or deletions, and 2.6% were splice site, and 51.7% of mutations were at CpG dinucleotides. Mutations designated as DNA contact mutations represented 23.7% of all mutations; structural mutations accounted for 58.7% of all mutations.

Compared with controls, there were no statistically significant age or gender differences for those with or without p53 mutations (Table 2), although people with p53 Wt were slightly older and more likely to be female than were people with a p53 mutation. Never using aspirin or NSAIDs on a regular basis, smoking cigarettes, having a large BMI, and being more sedentary were traits reported more commonly by cases, both those with and without p53 mutations, than by controls.

Colon cancer estimates of association with physical inactivity, BMI, not using aspirin/NSAIDs, and smoking were similar for those with and without a p53 mutation compared with controls (Table 3). However, cases with a p53 mutation were slightly more likely to consume a Western Diet compared with controls (OR, 2.03; 95% CI, 1.53–2.69) than were cases with p53 Wt (OR, 1.57; 95% CI, 1.20–2.06). Specific components of the Western dietary pattern that were most strongly associated with p53 specific disease pathway, as indicated by comparing cases with and without p53 mutations, were diets that contributed to a high glycemic index and were high in sugar (OR, 1.50; 95% CI, 1.06–2.13) and diets high in red meat, fast food, and trans-fatty acids (OR, 1.38; 95% CI, 1.00–1.80; data not shown in table). Other dietary factors, including total energy intake, dietary folate, calcium, fiber, and specific foods were not associated with overall p53 mutations. Additional adjustment for other diet and lifestyle factors did not alter the observed associations.

Gender and age-specific associations were observed for diet (data not shown in table). The high GI/sugar diet appeared to be associated with greater risk of a p53 mutation compared to controls in women than in men (OR for women, 1.94; 95% CI, 1.23–3.06 and OR for men, 1.22; 95% CI, 0.83–1.77). Glycemic load appeared to be specifically associated with a p53 disease pathway for women (OR for female cases with p53 mutations to p53 Wt, 1.87; 95% CI, 1.10–3.17). The red meat/fast food/trans-fatty acid diet appeared to have a greater impact on developing a p53 mutation among cases diagnosed at age 65 or older than among cases diagnosed after age 65 (OR comparing p53 mutation to controls for <65 years, 1.66; 95% CI, 1.11–2.49 and OR for ≥65 years, 2.13; 95% CI, 1.49–3.05) than for p53 Wt compared with controls (OR for <65 years, 1.40; 95% CI, 0.94–2.07 and OR for ≥65 years, 1.34; 95% CI, 0.95–2.38). Among older cases, the association with red meat/fast food/trans-fatty acid diet between those with and without a p53 mutation was significantly different (OR, 1.59; 95% CI, 1.02–2.46).

Additional assessment comparing specific types of p53 mutations to controls (Table 4) showed that Western dietary pattern overall and specific components of Western dietary pattern were associated with specific p53 mutations. Cases with transition and missense mutations were significantly more likely to eat a diet with a high glycemic load than cases without a p53 mutation (OR transition mutation cases compared with case p53 Wt, 1.77; 95% CI, 1.20–2.59 and OR for missense mutation compared with p53 Wt, 1.72; 95% CI, 1.19–2.50). High levels of red meat/fast food/trans-fatty acid diet also were significantly associated with missense, transition, transversion, and CpG mutations. Cases who consumed a high red meat/fast food/trans-fatty acid diet with a missense p53 mutation were significantly different from p53 Wt cases (OR for missense, 1.40; 95% CI, 1.00–1.98). Physical inactivity, large BMI, and cigarette smoking showed slightly stronger associations with p53 transversion mutations, although these differences were not statistically different from those detected in p53 Wt cases. Missense and stop codon mutations were slightly more associated with not using NSAIDs when compared with controls, although these associations were not statistically different from those observed for p53 Wt (Table 3).

Diets with a high glycemic load were more strongly associated with mutations in the L2 loop and at the Arg273 hot spot when compared with controls (Table 5) and compared with cases who were p53 Wt (data not shown in table); high levels of these diets also were slightly more associated with mutations that influence protein structure. Diets high in red meat/fast food/trans-fatty acid were significantly associated with mutations that influenced protein structure when compared with controls (Table 5) or cases without p53 mutations (OR cases with mutation in L2 loop compared with p53 Wt, 2.44; 95% CI, 1.19–5.02 and OR cases with p53 mutation in protein structure compared with p53 Wt, 1.58; 95% CI, 1.07–2.32).

Mutations of the p53 tumor suppressor gene are some of the most commonly observed genetic alterations in human cancer (1, 2, 3, 4, 5, 6). In this population-based study, we detected p53 mutations in 47.1% of all colon tumors. This is comparable with other reports using similar methods to detect alterations (6, 19, 22, 23). As previously reported (6), the majority of mutations were missense in nature. Although few large-scale studies, and no population-based studies, have attempted, to date, to look at location of mutation on the gene, our data are comparable with those reports that exist. Our findings suggest that components of a Western-style diet are associated with p53 mutations. Associations with a diet high with a high glycemic load were more pronounced among women than among men; associations with a diet high in red meat, fast food, and trans-fatty acid were more marked among people diagnosed when older than when younger.

Most epidemiological studies examining p53 alterations in conjunction with diet and lifestyle factors have used IHC rather than sequencing to detect genetic alterations (19, 24). Most of these studies have had limited power. However, Voskuil et al.(19) studied 185 cases of colon cancer and 259 controls using both IHC and sequencing. IHC results showed 44% of cases with overexpression; sequencing results detected mutations in 32% of cases. Slightly stronger dietary associations were detected by IHC, although the strongest associations were detected among those without alterations in p53. In the study by Voskuil et al.(19), saturated fat appeared to have a greater influence on transversion mutations (OR, 2.0; 95% CI, 0.97–4.1 for interquartile range of intake) than other types of mutations.

Freedman et al.(24) found slightly stronger associations for most diet and lifestyle factors among those with p53+ tumors than those with p53− tumors when compared with controls in a study of 163 cases and 326 controls. In the study by Freedman et al.(24), tumors were considered p53+ when ≥20% cells were stained positive by IHC. Beef consumption was more strongly associated with p53− tumors when compared with controls than to p53+ tumors compared with controls; comparisons between p53+ and p53− tumors were not made (24). Using the same set of cases, Freedman et al.(25) also examined cigarette smoking and found that smoking cigarettes was associated with p53 independent pathways because a much stronger association was observed when comparing p53+ cases to controls than when comparing p53− cases to controls. Zhang et al.(26), in a study of 107 patients with Dukes stage C colorectal cancer, used ≥25% positive cells to define a p53+ phenotype. They observed no differences in association between those who were p53+ versus those who were p53− for BMI, occupational activity, smoking cigarettes, drinking alcohol, or parity, although there were suggestions of a greater likelihood of having a p53+ tumor with bigger body weight.

These data represent the largest single data set of mutational analysis of colon tumors sequenced to date to our knowledge. However, because this is the first study to be able to evaluate types and location of mutations at this level of detail, these analyses can be considered exploratory and hypothesis generating. The majority of p53 mutations occur in the core domain that contains the sequence-specific DNA binding activity of the p53 protein (residues 102–292; 18). It is thought that the core domain is central to understanding how p53 binds DNA and how tumorigenic mutations inactivate p53. The core domain structure consists of a β sandwich that acts as a scaffold for two large loops and a LSH. One class of mutations involves residues that contact the DNA; mutations in this area can be attributed to loss of critical DNA contacts that inactivate the p53 gene. Other mutations appear to be critical for the stable folding of the core domain, and loss of DNA binding by these mutations can be attributed to structural defects. We observed that the Arg273 hot spot, a contact mutation located in the LSH motif, was influenced by a diet high in red meat, fast food, and trans-fatty acids. Other than individual hot spots, attempts have not been made to examine type or location of mutation in conjunction with diet and lifestyle factors. Associations appeared to be slightly stronger for mutations located on the L2 loop. Mutations located in specific areas of the gene may be important etiologically and may provide insight into different functional properties of the gene (8, 18).

Because of the size of the data set and genetic analyses by sequencing and SSCP, we have been able to evaluate diet and lifestyle associations with p53 in more detail than has been done previously. However, for many factors, including physical activity, BMI, and using aspirin/NSAIDs, associations were similar for those with and without mutations, suggesting their association with many disease pathways. We observed the strongest associations for missense mutations, although, given that these types of mutations were more prevalent, we also had more power to detect significant associations. Associations with a Western dietary pattern were stronger among cases who had a p53 mutation compared with controls than among cases who were p53 Wt compared with controls. Certain components of a Western dietary pattern appear to account for the association with a p53 disease pathway. These components, one representing high glycemic load and the other representing diets characterized by high intakes of red meat, fast food, and trans-fatty acids, imply that factors associated with the insulin and the IGF system levels may be associated with a p53 disease pathway. Controlled studies suggest that Wt p53 is necessary for the IGF-IR to function properly (27, 28). Studies have shown that sensitivity of tumor cells to circulating IGF-I is dependent on IGF-IR number; functional IGF-IRs are necessary for tumor formation and progression (29, 30).

This study advances our understanding of disease pathways and how diet and lifestyle factors are associated with specific pathways. Whereas p53 is considered to occur later in the carcinogenic process, only 13.8% of tumors in this study had both a p53 and Ki-ras mutation and 3.2% of tumors had both a p53 mutation and microsatellite instability. In our previous work, we have shown that cigarette smoking and alcohol consumption are associated with microsatellite instability (31, 32). Dietary components also were associated with specific types of Ki-ras mutations (7): G→A mutations of the second base of codon 12 were associated with dietary factors hypothesized as being associated with DNA methylation, i.e., folate, vitamin B6, and vitamin B12; G→A mutations of the second base of codon 13 dietary factors were associated with insulin levels, i.e., carbohydrates, refined grains, and glycemic index; and G→T mutations on the second base of codon 12 were associated with dietary fat, saturated fat, and monounsaturated fat. Additional exploration of interrelationship of diet and lifestyle factors and disease pathways is needed.

This study has several strong points, including the fact that it represents a population-based sample rather than a sample of cases that are derived from a limited number of clinics and/or hospitals. The dietary and other data were collected in a very rigorous manner. We attempted to collect tumor blocks on all cases identified in Utah and KPMCP and obtained blocks for the majority of cases in both centers (97% in Utah and 85% in KPMCP). Mutational status of the larger sample does not vary from the sample of interviewed cases. However, it is possible that despite rigorous laboratory techniques that included SSCP followed by sequencing detected variants that mutations could be missed. Likewise, because only the hot spots of the gene were sequenced it is possible that undetected mutations in other parts of the gene could dilute associations; however, studies have shown that almost 90% of all p53 mutations in colon cancer are in these hot spots.

In summary, dietary components of a Western-style diet appear to contribute to a p53-colon cancer disease pathway. These components, one representing a diet associated with a high glycemic load and the other component representing a diet high in meat, fast food, and trans-fatty acids, appear to contribute most importantly to this disease pathway. These data suggest the importance of diet in relation to colon cancer and further suggest a specific disease pathway whereby these dietary factors operate.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1

This study was funded by National Cancer Institute CA48998 and CA61757 (to M. L. S.), the Utah Cancer Registry, which is funded by Contract N01-PC-67000 from the National Cancer Institute, with additional support from the State of Utah Department of Health, the Northern California Cancer Registry, and the Sacramento Tumor Registry.

3

The abbreviations used are: KPMCP, Kaiser Permanente Medical Care Program; NSAID, nonsteroidal anti-inflammatory drugs; BMI, body mass index; SSCP, single-strand conformational polymorphism; LSH, loop-sheet-helix; Wt, wild type; OR, odds ratio; CI, confidence interval; IHC, immunohistochemistry; IGF, insulin-like growth factor; IGF-IR, IGF-I receptor; GI, glycemic index.

Table 1

Description of p53 mutations in the population

Total n (%)Men n (%)Women n (%)<65 n (%)>65 n (%)
p53 Wt 772 (52.9) 409 (51.6) 363 (54.6) 321 (51.5) 451 (54.0) 
p53 mutations 686 (47.1)a 384 (48.4) 302 (45.4) 302 (48.5) 384 (46.0) 
 Transition 528 (77.0) 287 (74.7) 241 (79.8) 240 (79.5) 288 (75.0) 
 Transversion 117 (17.1) 71 (18.5) 46 (15.2) 55 (18.2) 62 (16.1) 
 Missense 562 (81.9) 311 (81.0) 251 (83.1) 250 (82.8) 312 (81.3) 
 Frameshift 65 (9.5) 36 (9.4) 29 (9.6) 22 (7.3) 43 (11.2) 
 Stop 68 (9.9) 38 (9.9) 30 (9.9) 36 (11.9) 32 (8.3) 
 In-frame insertion/deletion 20 (2.9) 15 (3.9) 5 (1.7) 5 (1.7) 15 (3.9) 
 Splice site 18 (2.6) 10 (2.6) 8 (2.6) 10 (3.3) 8 (2.1) 
 CpG dinucleotides 355 (51.7) 201 (52.3) 154 (51.0) 163 (54.0) 192 (50.0) 
 R273 80 (11.7) 44 (11.5) 36 (11.9) 42 (13.9) 38 (9.9) 
 R248 79 (11.5) 39 (10.2) 40 (13.2) 30 (9.9) 49 (12.8) 
 L2 loop 110 (16.0) 66 (17.2) 44 (14.6) 54 (17.9) 56 (14.6) 
 L3 loop 143 (20.8) 74 (19.3) 69 (22.8) 63 (20.9) 80 (20.8) 
 LSH 189 (27.6) 102 (26.6) 87 (28.8) 86 (28.5) 103 (26.8) 
 β Sandwich 64 (9.3) 40 (10.4) 24 (7.9) 23 (7.6) 41 (10.7) 
 Contact 165 (24.1) 86 (22.4) 79 (26.2) 73 (24.2) 92 (24.0) 
 Structure 397 (57.9) 225 (58.6) 172 (57.0) 177 (58.6) 220 (57.3) 
 Denaturing 131 (19.1) 80 (20.8) 51 (16.9) 62 (20.5) 69 (18.0) 
Total n (%)Men n (%)Women n (%)<65 n (%)>65 n (%)
p53 Wt 772 (52.9) 409 (51.6) 363 (54.6) 321 (51.5) 451 (54.0) 
p53 mutations 686 (47.1)a 384 (48.4) 302 (45.4) 302 (48.5) 384 (46.0) 
 Transition 528 (77.0) 287 (74.7) 241 (79.8) 240 (79.5) 288 (75.0) 
 Transversion 117 (17.1) 71 (18.5) 46 (15.2) 55 (18.2) 62 (16.1) 
 Missense 562 (81.9) 311 (81.0) 251 (83.1) 250 (82.8) 312 (81.3) 
 Frameshift 65 (9.5) 36 (9.4) 29 (9.6) 22 (7.3) 43 (11.2) 
 Stop 68 (9.9) 38 (9.9) 30 (9.9) 36 (11.9) 32 (8.3) 
 In-frame insertion/deletion 20 (2.9) 15 (3.9) 5 (1.7) 5 (1.7) 15 (3.9) 
 Splice site 18 (2.6) 10 (2.6) 8 (2.6) 10 (3.3) 8 (2.1) 
 CpG dinucleotides 355 (51.7) 201 (52.3) 154 (51.0) 163 (54.0) 192 (50.0) 
 R273 80 (11.7) 44 (11.5) 36 (11.9) 42 (13.9) 38 (9.9) 
 R248 79 (11.5) 39 (10.2) 40 (13.2) 30 (9.9) 49 (12.8) 
 L2 loop 110 (16.0) 66 (17.2) 44 (14.6) 54 (17.9) 56 (14.6) 
 L3 loop 143 (20.8) 74 (19.3) 69 (22.8) 63 (20.9) 80 (20.8) 
 LSH 189 (27.6) 102 (26.6) 87 (28.8) 86 (28.5) 103 (26.8) 
 β Sandwich 64 (9.3) 40 (10.4) 24 (7.9) 23 (7.6) 41 (10.7) 
 Contact 165 (24.1) 86 (22.4) 79 (26.2) 73 (24.2) 92 (24.0) 
 Structure 397 (57.9) 225 (58.6) 172 (57.0) 177 (58.6) 220 (57.3) 
 Denaturing 131 (19.1) 80 (20.8) 51 (16.9) 62 (20.5) 69 (18.0) 
a

The number of individuals with a p53 mutation was 686. Because some people had multiple mutations, the total number of mutations does not add up to 686. Percentages are based on the percentage of people with the mutation rather than the percentage of all mutations.

Table 2

Description of population by p53 mutation status

p53 mutation (n = 686) n (%)p53 Wt (n = 772) n (%)Controls (n = 2410) n (%)
Age    
 <50 58 (8.5) 61 (7.9) 229 (9.5) 
 51–64 244 (35.6) 260 (33.7) 760 (31.5) 
 65–69 132 (19.2) 142 (18.4) 489 (20.3) 
 70–79 252 (36.7) 309 (40.0) 932 (38.7) 
 χ2a 0.24 0.28  
Gender    
 Men 384 (56.9) 409 (53.0) 1290 (53.5) 
 Women 302 (44.0) 363 (47.0) 1120 (46.5) 
 χ2 0.27 0.79  
Aspirin/NSAID (regular use)    
 No 420 (61.2) 481 (62.3) 1260 (52.3) 
 Yes 266 (38.8) 291 (37.7) 1150 (47.7) 
 χ2 <0.01 <0.01  
Cigarette smoking status    
 Never 281 (41.2) 337 (43.8) 1121 (46.6) 
 <20 cigarettes/day 135 (19.8) 142 (18.5) 498 (20.7) 
 ≥20 cigarettes/day 266 (39.0) 290 (37.7) 786 (32.7) 
 χ2 <0.01 0.03  
BMI [wt (kg)/ht (m)2   
 <25 235 (34.3) 252 (32.6) 955 (39.6) 
 25–29 217 (31.7) 281 (36.4) 831 (34.5) 
 >29 234 (34.2) 239 (31.0) 624 (25.9) 
 χ2 <0.01 <0.01  
Long-term vigorous physical activity    
 None 189 (27.6) 214 (27.7) 535 (22.2) 
 Intermediate 277 (40.4) 329 (42.6) 985 (40.9) 
 High 220 (32.1) 229 (29.7) 890 (36.9) 
 χ2 <0.01 <0.01  
p53 mutation (n = 686) n (%)p53 Wt (n = 772) n (%)Controls (n = 2410) n (%)
Age    
 <50 58 (8.5) 61 (7.9) 229 (9.5) 
 51–64 244 (35.6) 260 (33.7) 760 (31.5) 
 65–69 132 (19.2) 142 (18.4) 489 (20.3) 
 70–79 252 (36.7) 309 (40.0) 932 (38.7) 
 χ2a 0.24 0.28  
Gender    
 Men 384 (56.9) 409 (53.0) 1290 (53.5) 
 Women 302 (44.0) 363 (47.0) 1120 (46.5) 
 χ2 0.27 0.79  
Aspirin/NSAID (regular use)    
 No 420 (61.2) 481 (62.3) 1260 (52.3) 
 Yes 266 (38.8) 291 (37.7) 1150 (47.7) 
 χ2 <0.01 <0.01  
Cigarette smoking status    
 Never 281 (41.2) 337 (43.8) 1121 (46.6) 
 <20 cigarettes/day 135 (19.8) 142 (18.5) 498 (20.7) 
 ≥20 cigarettes/day 266 (39.0) 290 (37.7) 786 (32.7) 
 χ2 <0.01 0.03  
BMI [wt (kg)/ht (m)2   
 <25 235 (34.3) 252 (32.6) 955 (39.6) 
 25–29 217 (31.7) 281 (36.4) 831 (34.5) 
 >29 234 (34.2) 239 (31.0) 624 (25.9) 
 χ2 <0.01 <0.01  
Long-term vigorous physical activity    
 None 189 (27.6) 214 (27.7) 535 (22.2) 
 Intermediate 277 (40.4) 329 (42.6) 985 (40.9) 
 High 220 (32.1) 229 (29.7) 890 (36.9) 
 χ2 <0.01 <0.01  
a

χ2 compares p53 mutation to control and p53 Wt to control.

Table 3

Associationsa between diet and lifestyle factors in cases with and without p53 mutations compared with controls

OR (referent)OR (95% CI)OR (95% CI)P trend
Diet     
 Western Low Intermediate High  
n cases M/Wt/controls 97/123/482 402/470/1461 187/179/467  
 Mutation 1.00 1.37 (1.07–1.75) 2.03 (1.53–2.69) <0.01 
 Wt 1.00 1.28 (1.02–1.60) 1.57 (1.20–2.06) 0.02 
 GI/Sugar Low Intermediate High  
n cases M/Wt/controls 86/124/382 420/477/1490 180/171/538  
 Mutation 1.00 1.25 (0.96–1.61) 1.48 (1.11–1.98) <0.01 
 Wt 1.00 0.99 (0.79–1.24) 0.98 (0.75–1.28) 0.53 
 Red meat/fast food/trans-fatty acid Low Intermediate High  
n cases M/Wt/controls 113/147/553 366/434/1356 207/191/521  
 Mutation 1.00 1.28 (1.01–1.62) 1.92 (1.47–2.50) <0.01 
 Wt 1.00 1.18 (0.95–1.46) 1.39 (1.08–1.80) 0.01 
Lifestyle     
Physical activity High Intermediate Low  
n cases M/Wt/controls 220/229/890 277/329/985 189/214/535  
 Mutation 1.00 1.16 (0.95–1.42) 1.54 (1.22–1.93) <0.01 
 Wt 1.00 1.31 (1.08–1.60) 1.59 (1.27–1.99) <0.01 
 BMI [wt (kg)/ht (m)2<25 25–29 >29  
n cases M/Wt/controls 235/252/965 217/281/831 234/239/624  
 Mutation 1.00 0.99 (0.80–1.24) 1.43 (1.16–1.76) <0.01 
 Wt 1.00 1.24 (1.00–1.53) 1.49 (1.22–1.83) <0.01 
 Smoking (cigarettes/day) None <20 ≥20  
n cases M/Wt/controls 281/337/1121 135/142/498 266/290/786  
 Mutation 1.00 1.08 (0.86–1.36) 1.33 (1.09–1.62) <0.01 
 Wt 1.00 0.95 (0.76–1.19) 1.25 (1.04–1.51) <0.01 
 Aspirin/NSAID (regular use) Yes No   
n cases M/Wt/controls 266/291/1150 420/481/1260   
 Mutation 1.00 1.43 (1.20–1.71)   
 Wt 1.00 1.53 (1.29–1.81)   
OR (referent)OR (95% CI)OR (95% CI)P trend
Diet     
 Western Low Intermediate High  
n cases M/Wt/controls 97/123/482 402/470/1461 187/179/467  
 Mutation 1.00 1.37 (1.07–1.75) 2.03 (1.53–2.69) <0.01 
 Wt 1.00 1.28 (1.02–1.60) 1.57 (1.20–2.06) 0.02 
 GI/Sugar Low Intermediate High  
n cases M/Wt/controls 86/124/382 420/477/1490 180/171/538  
 Mutation 1.00 1.25 (0.96–1.61) 1.48 (1.11–1.98) <0.01 
 Wt 1.00 0.99 (0.79–1.24) 0.98 (0.75–1.28) 0.53 
 Red meat/fast food/trans-fatty acid Low Intermediate High  
n cases M/Wt/controls 113/147/553 366/434/1356 207/191/521  
 Mutation 1.00 1.28 (1.01–1.62) 1.92 (1.47–2.50) <0.01 
 Wt 1.00 1.18 (0.95–1.46) 1.39 (1.08–1.80) 0.01 
Lifestyle     
Physical activity High Intermediate Low  
n cases M/Wt/controls 220/229/890 277/329/985 189/214/535  
 Mutation 1.00 1.16 (0.95–1.42) 1.54 (1.22–1.93) <0.01 
 Wt 1.00 1.31 (1.08–1.60) 1.59 (1.27–1.99) <0.01 
 BMI [wt (kg)/ht (m)2<25 25–29 >29  
n cases M/Wt/controls 235/252/965 217/281/831 234/239/624  
 Mutation 1.00 0.99 (0.80–1.24) 1.43 (1.16–1.76) <0.01 
 Wt 1.00 1.24 (1.00–1.53) 1.49 (1.22–1.83) <0.01 
 Smoking (cigarettes/day) None <20 ≥20  
n cases M/Wt/controls 281/337/1121 135/142/498 266/290/786  
 Mutation 1.00 1.08 (0.86–1.36) 1.33 (1.09–1.62) <0.01 
 Wt 1.00 0.95 (0.76–1.19) 1.25 (1.04–1.51) <0.01 
 Aspirin/NSAID (regular use) Yes No   
n cases M/Wt/controls 266/291/1150 420/481/1260   
 Mutation 1.00 1.43 (1.20–1.71)   
 Wt 1.00 1.53 (1.29–1.81)   
a

Adjusted for age and gender; comparisons made to population-based controls. M, mutation.

Table 4

Associationsa between dietary and lifestyle factors and specific types of p53 mutations compared with controlsb

OR (referent)OR (95% CI)OR (95% CI)P trend
Diet     
 Western Low Intermediate High  
  Transition 1.00 1.30 (1.00–1.71) 1.94 (1.43–2.65) <0.01 
  Transversion 1.00 1.50 (0.85–2.65) 2.13 (1.13–4.03) <0.01 
  Missense 1.00 1.31 (1.01–1.71) 1.92 (1.42–2.60) <0.01 
  Frameshift 1.00 1.31 (0.67–2.56) 1.17 (0.50–2.77) 0.86 
  Stop codon 1.00 1.31 (0.63–2.74) 2.50 (1.13–5.54) 0.01 
  CpG 1.00 1.28 (0.93–1.76) 1.86 (1.29–2.68) <0.01 
 GI/Sugar     
  Transition 1.00 1.43 (1.06–1.93) 1.74 (1.25–2.43) <0.01 
  Transversion 1.00 0.97 (0.57–1.65) 1.21 (0.67–2.20) 0.23 
  Missense 1.00 1.33 (1.00–1.77) 1.69 (1.23–2.33) <0.01 
  Frameshift 1.00 0.91 (0.47–1.74) 0.53 (0.22–1.27) 0.20 
  Stop codon 1.00 1.23 (0.60–2.55) 1.25 (0.55–2.87) 0.96 
  CpG 1.00 1.37 (0.96–1.95) 1.54 (1.04–2.28) 0.05 
 Red meat/fast food/trans-fatty acid diet     
  Transition 1.00 1.10 (0.85–1.42) 1.83 (1.37–2.45) <0.01 
  Transversion 1.00 2.28 (1.23–4.25) 2.60 (1.31–5.16) 0.01 
  Missense 1.00 1.26 (0.98–1.63) 1.92 (1.14–2.56) <0.01 
  Frameshift 1.00 1.16 (0.61–2.20) 1.29 (0.59–2.82) 0.54 
  Stop codon 1.00 0.97 (0.51–1.86) 1.60 (0.78–3.28) 0.10 
  CpG 1.00 0.92 (0.68–1.25) 1.57 (1.12–2.22) <0.01 
Lifestyle     
 Physical activity High Intermediate Low  
  Transition 1.00 1.10 (0.88–1.38) 1.39 (1.08–1.80) <0.01 
  Transversion 1.00 1.80 (1.13–2.87) 2.48 (1.47–4.19) <0.01 
  Missense 1.00 1.22 (0.98–1.52) 1.59 (1.24–2.04) <0.01 
  Frameshift 1.00 0.99 (0.55–1.78) 1.18 (0.61–2.30) 0.62 
  Stop codon 1.00 1.26 (0.72–2.23) 1.48 (0.76–2.89) 0.07 
  CpG 1.00 1.19 (0.91–1.55) 1.51 (1.11–2.05) <0.01 
 BMI [wt (kg)/ht (m)2<25 25–29 >29  
  Transition 1.00 1.05 (0.83–1.32) 1.43 (1.13–1.80) <0.01 
  Transversion 1.00 0.94 (0.58–1.54) 1.93 (1.24–3.01) <0.01 
  Missense 1.00 0.98 (0.78–1.23) 1.52 (1.21–1.90) <0.01 
  Frameshift 1.00 0.92 (0.50–1.69) 1.24 (0.68–2.27) 0.12 
  Stop codon 1.00 1.60 (0.90–2.86) 1.33 (0.70–2.52) 0.16 
  CpG 1.00 1.04 (0.79–1.37) 1.37 (1.04–1.81) <0.01 
 Smoking (cigarettes/day) None <20 ≥20  
  Transition 1.00 0.95 (0.73–1.23) 1.27 (1.02–1.58) <0.01 
  Transversion 1.00 1.32 (0.80–2.19) 1.60 (1.04–2.47) <0.01 
  Missense 1.00 0.95 (0.74–1.23) 1.31 (1.06–1.62) <0.01 
  Frameshift 1.00 1.49 (0.81–2.74) 0.99 (0.54–1.84) 0.70 
  Stop codon 1.00 1.40 (0.76–2.60) 1.24 (0.70–2.21) 0.14 
  CpG 1.00 0.85 (0.62–1.17) 1.17 (0.90–1.51) 0.14 
 Aspirin/NSAID (regular use) Yes No   
  Transition 1.00 1.41 (1.16–1.71)   
  Transversion 1.00 1.27 (0.87–1.85)   
  Missense 1.00 1.37 (1.13–1.65)   
  Frameshift 1.00 1.84 (1.09–3.11)   
  Stop codon 1.00 2.12 (1.25–3.61)   
  CpG 1.00 1.41 (1.12–1.78)   
OR (referent)OR (95% CI)OR (95% CI)P trend
Diet     
 Western Low Intermediate High  
  Transition 1.00 1.30 (1.00–1.71) 1.94 (1.43–2.65) <0.01 
  Transversion 1.00 1.50 (0.85–2.65) 2.13 (1.13–4.03) <0.01 
  Missense 1.00 1.31 (1.01–1.71) 1.92 (1.42–2.60) <0.01 
  Frameshift 1.00 1.31 (0.67–2.56) 1.17 (0.50–2.77) 0.86 
  Stop codon 1.00 1.31 (0.63–2.74) 2.50 (1.13–5.54) 0.01 
  CpG 1.00 1.28 (0.93–1.76) 1.86 (1.29–2.68) <0.01 
 GI/Sugar     
  Transition 1.00 1.43 (1.06–1.93) 1.74 (1.25–2.43) <0.01 
  Transversion 1.00 0.97 (0.57–1.65) 1.21 (0.67–2.20) 0.23 
  Missense 1.00 1.33 (1.00–1.77) 1.69 (1.23–2.33) <0.01 
  Frameshift 1.00 0.91 (0.47–1.74) 0.53 (0.22–1.27) 0.20 
  Stop codon 1.00 1.23 (0.60–2.55) 1.25 (0.55–2.87) 0.96 
  CpG 1.00 1.37 (0.96–1.95) 1.54 (1.04–2.28) 0.05 
 Red meat/fast food/trans-fatty acid diet     
  Transition 1.00 1.10 (0.85–1.42) 1.83 (1.37–2.45) <0.01 
  Transversion 1.00 2.28 (1.23–4.25) 2.60 (1.31–5.16) 0.01 
  Missense 1.00 1.26 (0.98–1.63) 1.92 (1.14–2.56) <0.01 
  Frameshift 1.00 1.16 (0.61–2.20) 1.29 (0.59–2.82) 0.54 
  Stop codon 1.00 0.97 (0.51–1.86) 1.60 (0.78–3.28) 0.10 
  CpG 1.00 0.92 (0.68–1.25) 1.57 (1.12–2.22) <0.01 
Lifestyle     
 Physical activity High Intermediate Low  
  Transition 1.00 1.10 (0.88–1.38) 1.39 (1.08–1.80) <0.01 
  Transversion 1.00 1.80 (1.13–2.87) 2.48 (1.47–4.19) <0.01 
  Missense 1.00 1.22 (0.98–1.52) 1.59 (1.24–2.04) <0.01 
  Frameshift 1.00 0.99 (0.55–1.78) 1.18 (0.61–2.30) 0.62 
  Stop codon 1.00 1.26 (0.72–2.23) 1.48 (0.76–2.89) 0.07 
  CpG 1.00 1.19 (0.91–1.55) 1.51 (1.11–2.05) <0.01 
 BMI [wt (kg)/ht (m)2<25 25–29 >29  
  Transition 1.00 1.05 (0.83–1.32) 1.43 (1.13–1.80) <0.01 
  Transversion 1.00 0.94 (0.58–1.54) 1.93 (1.24–3.01) <0.01 
  Missense 1.00 0.98 (0.78–1.23) 1.52 (1.21–1.90) <0.01 
  Frameshift 1.00 0.92 (0.50–1.69) 1.24 (0.68–2.27) 0.12 
  Stop codon 1.00 1.60 (0.90–2.86) 1.33 (0.70–2.52) 0.16 
  CpG 1.00 1.04 (0.79–1.37) 1.37 (1.04–1.81) <0.01 
 Smoking (cigarettes/day) None <20 ≥20  
  Transition 1.00 0.95 (0.73–1.23) 1.27 (1.02–1.58) <0.01 
  Transversion 1.00 1.32 (0.80–2.19) 1.60 (1.04–2.47) <0.01 
  Missense 1.00 0.95 (0.74–1.23) 1.31 (1.06–1.62) <0.01 
  Frameshift 1.00 1.49 (0.81–2.74) 0.99 (0.54–1.84) 0.70 
  Stop codon 1.00 1.40 (0.76–2.60) 1.24 (0.70–2.21) 0.14 
  CpG 1.00 0.85 (0.62–1.17) 1.17 (0.90–1.51) 0.14 
 Aspirin/NSAID (regular use) Yes No   
  Transition 1.00 1.41 (1.16–1.71)   
  Transversion 1.00 1.27 (0.87–1.85)   
  Missense 1.00 1.37 (1.13–1.65)   
  Frameshift 1.00 1.84 (1.09–3.11)   
  Stop codon 1.00 2.12 (1.25–3.61)   
  CpG 1.00 1.41 (1.12–1.78)   
a

Adjusted for age and gender.

b

For associations between Wt and controls, see Table 3.

Table 5

Dietary associationsa between cases with p53 mutations by location and functional definitions compared with controls

OR (referent)OR (95% CI)OR (95% CI)P trend
GI/Sugar Low Intermediate High  
Location     
 Arg273 1.00 1.16 (0.58–2.32) 1.77 (0.84–3.73) 0.03 
 Arg248 1.00 1.51 (0.74–3.10) 1.35 (0.60–3.07) 0.94 
 L2 loop 1.00 1.13 (0.61–2.09) 2.11 (1.11–4.01) <0.01 
 L3 loop 1.00 1.49 (0.87–2.57) 1.51 (0.82–2.78) 0.88 
 LSH 1.00 1.13 (0.43–3.01) 1.48 (0.48–4.21) 0.10 
Function     
 DNA contact 1.00 1.31 (0.80–2.14) 1.53 (0.89–2.65) 0.16 
 Protein structure 1.00 1.36 (0.97–1.90) 1.78 (1.23–2.57) <0.01 
 Denature 1.00 1.44 (0.82–2.52) 1.46 (0.78–2.74) 0.37 
Red meat/fast food/ trans-fatty acid     
Location     
 Arg273 1.00 1.29 (0.69–2.42) 1.83 (0.90–3.70) 0.02 
 Arg248 1.00 0.75 (0.43–1.31) 1.26 (0.67–2.39) 0.68 
 L2 loop 1.00 2.20 (1.15–4.22) 3.42 (1.70–6.86) <0.01 
 L3 loop 1.00 0.93 (0.60–1.45) 1.54 (0.94–2.54) 0.26 
 LSH 1.00 2.19 (0.75–6.41) 2.93 (0.91–9.49) 0.06 
Function     
 DNA contact 1.00 0.95 (0.63–1.42) 1.44 (0.90–2.30) 0.08 
 Protein structure 1.00 1.47 (1.08–2.01) 2.19 (1.55–3.08) <0.01 
 Denature 1.00 1.06 (0.66–1.69) 1.65 (0.97–2.80) 0.11 
OR (referent)OR (95% CI)OR (95% CI)P trend
GI/Sugar Low Intermediate High  
Location     
 Arg273 1.00 1.16 (0.58–2.32) 1.77 (0.84–3.73) 0.03 
 Arg248 1.00 1.51 (0.74–3.10) 1.35 (0.60–3.07) 0.94 
 L2 loop 1.00 1.13 (0.61–2.09) 2.11 (1.11–4.01) <0.01 
 L3 loop 1.00 1.49 (0.87–2.57) 1.51 (0.82–2.78) 0.88 
 LSH 1.00 1.13 (0.43–3.01) 1.48 (0.48–4.21) 0.10 
Function     
 DNA contact 1.00 1.31 (0.80–2.14) 1.53 (0.89–2.65) 0.16 
 Protein structure 1.00 1.36 (0.97–1.90) 1.78 (1.23–2.57) <0.01 
 Denature 1.00 1.44 (0.82–2.52) 1.46 (0.78–2.74) 0.37 
Red meat/fast food/ trans-fatty acid     
Location     
 Arg273 1.00 1.29 (0.69–2.42) 1.83 (0.90–3.70) 0.02 
 Arg248 1.00 0.75 (0.43–1.31) 1.26 (0.67–2.39) 0.68 
 L2 loop 1.00 2.20 (1.15–4.22) 3.42 (1.70–6.86) <0.01 
 L3 loop 1.00 0.93 (0.60–1.45) 1.54 (0.94–2.54) 0.26 
 LSH 1.00 2.19 (0.75–6.41) 2.93 (0.91–9.49) 0.06 
Function     
 DNA contact 1.00 0.95 (0.63–1.42) 1.44 (0.90–2.30) 0.08 
 Protein structure 1.00 1.47 (1.08–2.01) 2.19 (1.55–3.08) <0.01 
 Denature 1.00 1.06 (0.66–1.69) 1.65 (0.97–2.80) 0.11 
a

Adjusted for age and gender.

We thank Margaret Robertson at the University of Utah DNA Sequencing Core Facility, Linda Ballard at the University of Utah Genomics Core Facility, Melanie Nichols and Kristen Gruenthal, and Dr. Mark Leppert for laboratory support. We also thank Dr. Bette Caan, Dr. John Potter, Judy Morse, and Leslie Palmer for their data collection efforts.

1
Baker S. J., Markowitz S., Fearon E. R., Willson J. K., Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53.
Science (Wash. DC)
,
249
:
912
-915,  
1990
.
2
Chen F., Chang D., Goh M., Klibanov S. A., Ljungman M. Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors.
Cell Growth Differ.
,
11
:
239
-246,  
2000
.
3
Vogelstein B., Fearon E. R., Hamilton S. R., Kern S. E., Presinger B. A., Leppert M., Nakamura Y., White R., Smits A. M. M., Boss J. L. Genetic alterations during colorectal tumor development.
N. Engl. J. Med.
,
319
:
525
-532,  
1988
.
4
Baker S. J., Preisinger A. C., Jessup J. M., Paraskeva C., Markowitz S., Willson J. K., Hamilton S., Vogelstein B. p53 mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.
Cancer Res.
,
50
:
7717
-7722,  
1990
.
5
Hollstein M., Rice K., Greenblatt M. S., Soussi T., Fuchs R., Sorlie T., Hovig E., Smith-Sorenson B., Montesano R., Harris C. C. Database of p53 gene somatic mutations in human tumors and cell lines.
Nucleic Acids Res.
,
22
:
3551
-3555,  
1994
.
6
Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Cancer Res.
,
54
:
4855
-4878,  
1994
.
7
Slattery M. L., Curtin K., Anderson K., Ma K. N. I., Edwards S., Leppert M., Potter J., Schaffer D., Samowitz W. S. Associations between dietary intake and Ki-ras mutations in colon tumors: a population-based study.
Cancer Res.
,
60
:
6935
-6941,  
2000
.
8
Walker D. R., Bond J. R., Tarone R. E., Harris C. C., Makalowski W., Boguski M. S., Greenblatt M. S. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features.
Oncogene
,
18
:
211
-218,  
1999
.
9
Slattery M. L., Potter J. D., Caan B. J., Edwards S. L., Coates A., Berry D. T., Mori M. Energy balance and colon cancer: beyond physical activity.
Cancer Res.
,
57
:
75
-80,  
1997
.
10
Slattery M. L., Edwards S., Caan B., Kerber R. A., Potter J. D. Response rates among control subjects in case-control studies.
Ann. Epidemiol.
,
5
:
245
-249,  
1995
.
11
Edwards S., Slattery M. L., Mori M., Berry T. D., Palmer P. Objective system for interviewer performance evaluation for use in epidemiologic studies.
Am. J. Epidemiol.
,
140
:
1020
-1028,  
1994
.
12
Slattery M. L., Jacobs D. R., Jr. Assessment of ability to recall physical activity of several years ago.
Ann. Epidemiol.
,
5
:
292
-296,  
1995
.
13
Slattery M. L., Caan B., Duncan D., Berry T. D., Coates A., Kerber R. A computerized diet history questionnaire for epidemiologic studies.
J. Am. Diet. Assoc.
,
94
:
761
-766,  
1994
.
14
Liu K., Slattery M. L., Jacobs D. J., Cutter G., McDonald A., Van Horn L., Hilner J. E., Caan B., Bragg C., Dyer A., Havlik R. A study of the reliability and comparative validity of the CARDIA dietary history.
Ethn. Dis.
,
4
:
15
-27,  
1994
.
15
Slattery M. L, Benson J., Berry T. D., Duncan D., Edwards S. L., Caan B. J., Potter J. D. Dietary sugar and colon cancer.
Cancer Epidemiol. Biomark. Prev.
,
6
:
677
-685,  
1997
.
16
Slattery M. L., Edwards S. L., Palmer L., Curtin K., Morse J., Anderson K., Samowitz W. Use of archival tissue in epidemiologic studies: collection procedures and assessment of potential sources of bias.
Mutat. Res.
,
432
:
7
-14,  
2000
.
17
Bonner M. R., Ballard L. W. Considerations in adding mutation detection services to a sequencing core facility.
J. Biomol. Tech.
,
10
:
177
-186,  
1999
.
18
Cho Y., Gorina S., Jeffrey P. D., Pavletich N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.
Science (Wash. DC)
,
265
:
346
-355,  
1994
.
19
Voskuil D. W., Kampman E., van Kraats A. A., Balder H. F., van Muijen G. N. P., Goldrohm R. A., van’t Veer P p53 overexpression and p53 mutations in colon carcinomas: relation to dietary risk factors.
Int. J. Cancer
,
81
:
675
-681,  
1999
.
20
Slattery M. L., Boucher K. M., Caan B. J., Potter J. D., Ma K. N. Eating patterns and colon cancer.
Am. J. Epidemiol.
,
148
:
4
-16,  
1998
.
21
Slattery M. L., Edwards S. L., Ma K. N., Friedman G. F., Potter J. D. Physical activity and colon cancer: a public health perspective.
Ann. Epidemiol.
,
7
:
137
-145,  
1997
.
22
Tortola S., Marcuello E., Gonzalez I., Reyes G., Arribas R., Aiza G., Sancho F. J., Peinado M. A., Capella G. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not routine prognostic value in colorectal cancer.
J. Clin. Oncol.
,
17
:
1375
-1381,  
1999
.
23
Soong R., Grieu F., Robbins P., Dix B., Chen D., Parsons R., Houlse A., Iacopetta B. p53 alterations are associated with improved prognosis in distal colonic carcinomas.
Clin. Cancer Res.
,
3
:
1405
-1411,  
1997
.
24
Freedman A. N., Michalek A. M., Marshall J. R., Mettlin C. J., Petrelli N. J., Black J. D., Zhang Z. F., Satchidanand S., Asirwatham J. E. Familial and nutritional risk factors for p53 overexpression in colorectal cancer.
Cancer Epidemiol. Biomark. Prev.
,
5
:
285
-291,  
1996
.
25
Freedman A. N., Michalek A. M., Marshall J. R., Mettlin C., Petrelli N. J., Zhang Z. F., Black J. D., Satchidanand S., Asirwatham J. E. The relationship between smoking exposure and p53 overexpression in colorectal cancer.
Br. J. Cancer
,
73
:
902
-908,  
1996
.
26
Zhang A. F., Zeng Z. S., Sarkis A. S., Klimstra D. S., Charytonowicz E., Pollack D., Vena J., Guillem J., Marshall J. R., Cordon-Cardo C., Cohen A. M., Begg C. B. Family history of cancer, body weight, and p53 nuclear overexpression in Duke’s C colorectal cancer.
Br. J. Cancer
,
71
:
888
-893,  
1995
.
27
Girnita L., Girnita A., Brodin B., Xie Y., Nilsson G., Dricu A., Lundeberg J., Wejde J., Bartolazzi A., Winmna K. G., Larsson O. Increased expression of insulin-like growth factor I receptor in malignant cells expression aberrant p53: functional impact.
Cancer Res.
,
60
:
5278
-5283,  
2000
.
28
Werner H., Karnieli E., Rauscher F. J., LeRoith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene.
Proc. Natl. Acad. Sci. USA
,
93
:
8318
-8323,  
1996
.
29
Butler A. A., Yakar S., Gewolb I. H., Karas M., Okubo Y., LeRoith D. Insulin-like growth factor I receptor signal transduction: at the interface between physiology and cell biology.
Comp. Biochem. Physiol. B Biochem. Mol. Biol.
,
121
:
19
-26,  
1998
.
30
Butler A. A., Blakesley V. A., Poulaki V., Tsokos M., Wood T. L., LeRoith D., Pouliki V. Stimulation of tumor growth by recombinant human insulin-like growth factor I (IGF-I) is dependent on the dose and the level of IGF-I receptor expression.
Cancer Res.
,
58
:
3021
-3027,  
1998
.
31
Slattery M. L., Curtin K., Anderson K., Ma K. N., Ballard L., Edwards S., Leppert M., Potter J. D., Schaffer D., Samowitz W. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors.
J. Natl. Cancer Inst. (Bethesda)
,
92
:
1831
-1836,  
2000
.
32
Slattery M. L., Anderson K., Curtin K., Ma K. N., Schaffer D., Samowitz W. Dietary intake and microsatellite instability in colon tumors.
Int. J. Cancer
,
93
:
601
-607,  
2001
.